stop_circleTerminated/Withdrawn

Carcinoma, Non-Small-Cell Lung

Bayer Identifier:

12621

ClinicalTrials.gov Identifier:

NCT00558636

EudraCT Number:

Not Available

EU CT Number:

Not Available
A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel plus or minus Sorafenib (BAY43-9006) in Chemonaive Patients with Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

Trial purpose

The purpose of this study conducted in Asia-Pacific was to evaluate the efficacy and safety of Sorafenib in combination with paclitaxel and carboplatin versus placebo in combination with paclitaxel and carboplatin for chemonaive patients with unresectable stage IIIB (with effusion) or stage IV NSCLC. However, as indicated below, the study was terminated prematurely when the results from Study 11961 (NCT00300885), an earlier Phase 3 study of similar design in subjects with advanced NSCLC, showed an overall lack of efficacy and increased mortality in subjects with squamous subtype. The data available is presented as descriptive analyses, due to the limitations of implementing the statistical analysis plan.

Key Participants Requirements

Sex

Both

Age

18 Years
  • - Stage IIIB (with cytologically confirmed malignant pleural or pericardial effusion) or Stage IV histological or cytological confirmation of NSCLC (thoracentesis or pericardiocentesis is not necessary if a biopsy of the original tumor is available to confirm diagnosis of NSCLC)
    - Patients must have measurable disease according to response evaluation criteria in solid tumors (RECIST) criteria
    - Prior local radiotherapy is allowed if it is completed at least 3 weeks prior to the first dose of study drug, but the lesion which undergo RECIST assessment should not be in the field of the prior radiation
    - Prior surgery is allowed if it is performed at least 4 weeks prior to the first dose of study drug
    - 18 years and above
    - Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
    - Life expectancy of at least 12 weeks
    - Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to start of first dose:
    - Hemoglobin 9.0 g/dl
    - Absolute neutrophil count (ANC) 1,500/mm3
    - Platelet count 100,000/mm3
    - Total bilirubin < 1.5 times the upper limit of normal
    - alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal (< 5 x upper limit of normal for patients with liver involvement)
    - international normalized ratio (INR) < 1.5 and activated or adjusted partial thromboplastin time (APTT) within normal limits (1.2 times the lower limit of normal (LLN) to 1.2 times the upper limit of normal (ULN))
    - Creatinine - Ability to understand and the willingness to sign a written informed consent. A signed informed consent must be obtained prior to any study specific procedures

  • - Any prior systemic anticancer therapy including cytotoxic therapy, targeted agents, experimental therapy, adjuvant, or neo-adjuvant therapy for any current or prior diagnosis of NSCLC
    - Cardiac disease: Congestive heart failure > class II New York Heart Association (NYHA). Patients must not have unstable angina (anginal symptoms at rest) or new-onset angina (began within the last 3 months) or myocardial infarction within the past 6 months
    - Known brain metastasis. Patients with neurological symptoms should undergo at Computed Tomography (CT) scan/Magnetic Resonance Imaging (MRI) of the brain to exclude brain metastasis
    - Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
    - Uncontrolled hypertension defined as systolic blood pressure > 150 mm Hg or diastolic pressure > 90 mm Hg, despite optimal medical management
    - Known human immunodeficiency virus (HIV) infection
    - Active clinically serious infections > Common Terminology Criteria for Adverse Events (CTCAE) Grade 2
    - Thrombotic or embolic events such as cerebrovascular accident including transient ischemic attacks within the past 6 months
    - Pulmonary hemorrhage/bleeding event > CTCAE Grade 2 within 4 weeks of first dose of study drug
    - Any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose of study drug
    - Serious, non-healing wound, ulcer, or bone fracture
    - Evidence or history of bleeding diathesis or coagulopathy
    - Major surgery, open biopsy or significant traumatic injury within 4 weeks of first dose of study drug
    - Therapeutic anticoagulation with vitamin K antagonists such as warfarin, or with heparins or heparinoids. Low dose warfarin (1 mg daily, oral) is permitted if the INR remains < 1.5. Low-dose aspirin is permitted
    - Known or suspected allergy to sorafenib or any agent given in the course of this trial
    - Cancer other than NSCLC within 5 years prior to start of study treatment, EXCEPT cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumors
    - Concurrent cancer that is distinct in primary site or histology from NSCLC
    - Substance abuse, medical, psychological or social conditions that may interfere with the patients participation in the study or evaluation of the study results
    - Any condition that impairs patients ability to swallow whole pills
    - Any malabsorption condition
    - Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment
    - Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation, including the 30 days period after last study drug dosing. The investigator should advise the patient how to achieve an adequate contraception

Trial summary

Enrollment Goal
91
Trial Dates
September 2007 - May 2008
Phase
Phase 3
Could I Receive a placebo
Yes
Products
Nexavar (Sorafenib, BAY43-9006)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
Sun Yat-sen University Cancer CenterGuangzhou, 510060, China
Terminated
Fudan University Shanghai Cancer Centershanghai, 200032, China
Completed
PLA 81 HospitalNanjing, 210003, China
Terminated
Tata Memorial HospitalMumbai, 400012, India
Completed
Changhua Christian HospitalChanghua, 500, Taiwan
Completed
National Cancer CenterSingapore, 169610, Singapore
Completed
Nanfang Hospital.Guangzhou, 510515, China
Completed
Cancer Hospital, Chinese Academy of Medical SciencesBeijing, 100021, China
Terminated
Peking University Cancer HospitalBeijing, 100142, China
Completed
Peking Union Medical College HospitalBeijing, 100730, China
Completed
Shanghai Pulmonary Hospital, Tongji Universityshanghai, 200433, China
Completed
Sir Run Run Shaw HospitalHangzhou, 310016, China
Completed
Zhejiang Cancer HospitalHangzhou, (310022),, China
Completed
Southwest Hospital of 3rd Military Medical University.Chongqing, 400038, China
Terminated
National Cancer CenterGyeonggi-do, 410-769, Korea, Republic Of
Terminated
Korea University Anam HospitalSeoul, 136-705, Korea, Republic Of
Terminated
Sir Ganga Ram HospitalNew- Delhi, 110008, India
Completed
National Taiwan University HospitalTaipei, 100, Taiwan
Completed
National University Cancer Institute, SingaporeSingapore, 119228, Singapore
Completed
Chulalongkorn HospitalBangkok, 10330, Thailand
Completed
Ramathibodhi HospitalBangkok, Thailand
Terminated
Shatin, China

Primary Outcome

  • Progression Free Survival
    date_rangeTime Frame:
    Up to 5 months after randomization of the first patient
    enhanced_encryption
    Safety Issue:
    No

Secondary Outcome

  • Overall Survival (OS)
    date_rangeTime Frame:
    Up to 5 months after randomization of the first patient
    enhanced_encryption
    Safety Issue:
    No
  • Best tumor response (number of responses per category) according to Response Evaluation Criteria in Solid Tumors (RECIST)
    date_rangeTime Frame:
    Best tumor response assessed every 6 weeks by investigator during treatment up to 5 months after randomization of the first patient.
    enhanced_encryption
    Safety Issue:
    No
  • Duration of Response
    date_rangeTime Frame:
    Time from first documented objective response (complete repsonse or partial repsonse) to disease progression or death, or to last tumor assessment if censored, up to 5 months after randomization of the first patient.
    enhanced_encryption
    Safety Issue:
    No
  • Change from baseline of Lung Cancer Symptoms (LCS) score assessed at each treatment cycle (21 days per cycle) starting with Cycle 2
    date_rangeTime Frame:
    Change from baseline of LCS score assessed at each treatment cycle starting with Cycle 2 (Cycles 2, 3, 4, 5, 6, 7; 21 days per cycle) up to 5 months after randomization of the first patient.
    enhanced_encryption
    Safety Issue:
    No
  • Change from baseline of Health-Related Quality of Life (HRQoL) score assessed at treatment Cycle 3 and Cycle 5
    date_rangeTime Frame:
    Change from baseline of HRQoL score assessed (at treatment Cycle 3 and Cycles 5 [21 days per cycle]) up to 5 months after randomization of the first patient.
    enhanced_encryption
    Safety Issue:
    No
  • Change from baseline of Health-Related Quality of Life (HRQoL) score assessed at treatment Cycle 7
    date_rangeTime Frame:
    Change from baseline of HRQoL score assessed (at treatment Cycle 7 [21 days per cycle]) up to 5 months after randomization of the first patient.
    enhanced_encryption
    Safety Issue:
    No

Trial design

A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel plus or minus Sorafenib (BAY43-9006) in chemonaive patients with Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
Randomized
Blinding
Double Blind
Assignment
Parallel Assignment
Trial Arms
2

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.Click here to find results for studies related to Bayer Healthcare products.